For years researchers have been developing molecular imaging techniques that visualize hormonally active breast cancer cells — specifically those testing positive
for human epidermal growth factor receptor 2 (HER2).
Not exact matches
Triple - negative cancers are so called because they do not express
receptors for the hormones estrogen and progesterone, nor
for HER2 (
human epidermal growth factor 2), and hence patients with these cancers are not candidates
for treatment with modern hormonal therapies or the highly effective HER2 - targeted drug Herceptin (trastuzumab).
PALLAS: Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone
for Hormone
Receptor Positive (HR +) /
Human Epidermal Growth Factor Receptor 2 (HER2)- Negative Early Breast Cancer
GEP testing is recommended
for patients with early - stage, node - negative, estrogen
receptor (ER)-- positive,
human epidermal growth factor 2 (HER2)-- negative cancers.
Chemotherapy is a key part of the standard treatment regimen
for triple - negative breast cancer patients whose cancer lacks expression of estrogen and progesterone
receptors and the
human epidermal growth factor receptor 2...
Triple negative breast cancer is a type of breast cancer that does not express
receptors for the hormones estrogen and progesterone, or
for human epidermal growth factor.
The
human epidermal growth factor receptor - 2 (HER2) gene makes proteins responsible
for maintaining healthy cell
growth, division and repair of breast tissue.
These results, also presented at the 2015 European Cancer Congress (ECC2015, abstract # 5BA) today, which involve the group of 1,626 patients with a Recurrence Score between 0 and 10, demonstrated that 99.3 percent of node - negative, estrogen
receptor (ER)- positive,
human epidermal growth factor receptor 2 (HER2)- negative patients who met accepted guidelines
for recommending chemotherapy in addition to hormonal therapy, had no distant recurrence at five years after treatment with hormonal therapy alone.
Many women are «triple negative» No one yet knows precisely why, but African - American women are roughly twice as likely as white women to have triple - negative breast cancer — so called because tumor cells in this particularly aggressive form of the disease test negative
for estrogen
receptor (ER), progesterone
receptor (PR), and
human epidermal growth factor receptor 2 (HER - 2).
In highly proliferative lesions with increased Ki67, estrogen
receptor was negative, but
human epidermal growth factor receptor 2 was usually positive with a distribution that was similar to that reported
for human intraepithelial lesions (7).